HopeConnectLearn includes a website and social media channels where patients and caregivers can find information about this rare disease and tools to help empower patients in conversations with their physician, as well as patient stories.
"A hairy cell leukemia diagnosis or relapse or refractory experience can be daunting for patients, and connection with others navigating similar challenges can provide needed comfort and strength," said
Hairy cell leukemia is a rare blood cancer accounting for two to three percent of all cases of adult leukemias in the
This is often a slow growing, or indolent, form of cancer, and 90 percent of patients will have a normal life expectancy. About 40 percent of patients will relapse in 5-10 years following first treatment.iii_iv
"When facing a rare disease like hairy cell leukemia, patients derive hope from hearing directly from other patients and learning about their experiences," said
Join the HopeConnectLearn community online at www.hopeconnectlearn.com, on Twitter @HopeConnectLrn, Instagram @HopeConnectLearn and at www.Facebook.com/HopeConnectLearn.
About
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Based in
Learn more about
Information about
ISIN code Ticker code LEI | FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
For additional information, please contact:
Investors Tel.: +33 (0)4 30 30 30 30 investors@innate-pharma.com | Media Tel.: +1 240 801 0076 Tracy.Rossin@innate-pharma.com |
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in
_________________________
i
ii Troussard X, Cornet E. Hairy cell leukemia 2018: update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2017; 92(12): 1382-1390.
iii Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by
iv Grever MR, Blachly JS, Andritsos LA. Hairy cell leukemia: Update on molecular profiling and therapeutic advances. Blood Rev. 2014;28(5):197-203. doi:10.1016/j.blre.2014.06.003.
Source:
2020 GlobeNewswire, Inc., source